You are here:

budesonide-formoterol (Symbicort SMART)

Advice

following an abbreviated submission:

budesonide/formoterol (Symbicort® SMART®) is accepted for use within NHS Scotland.

Indication under review: the regular treatment of asthma where use of a combination (inhaled corticosteroid and a long-acting β2 adrenoceptor agonist is appropriate: patients not adequately controlled with inhaled corticosteroids and “as needed” short-acting β2 adrenoceptor agonists, or patients already adequately controlled on both inhaled corticosteroids and long-acting β2 adrenoceptor agonists. 

This advice relates to the extension of the license for Symbicort maintenance and reliever therapy (SMART®) to adolescents aged 12 to <18 years. 

SMC has previously accepted Symbicort maintenance and reliever therapy (SMART®) in adults.

Drug Details

Drug Name: budesonide-formoterol (Symbicort SMART)
SMC Drug ID: 1244/17
Manufacturer: AstraZeneca UK Ltd
Indication: the regular treatment of asthma where use of a combination (inhaled corticosteroid and a long-acting β2 adrenoceptor agonist is appropriate: patients not adequately controlled with inhaled corticosteroids and “as needed” short-acting β2 adrenoceptor agonists, or patients already adequately controlled on both inhaled corticosteroids and long-acting β2 adrenoceptor agonists.
BNF Category:
Sub Category: 3.2 Corticosteroids
Submission Type: Abbreviated Submission
Status: Accepted
Date Advice Published: 12 June 2017

Back